Therefore, optimizing the cytokine scheme, inducing CD3+CD56+ NKT-like cells sensitive to certain tumor cells, and making this immune cell safe, stable, and effective in killing tumor cells in patients with cancer is necessary. This evidence concerns the gene NCAM1 and cancer.